Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $128.7 billion by market cap ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...